Aventis and ImmunoGen entered into a collaboration agreement to discover, develop and commercialize antibody-based anticancer drugs. Aventis also has the option to extend the agreement for 1-2 years for a total commitment of US$99 M in addition to US$20-30 M in milestone payments for each product.